Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Ranibizumab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ranibizumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ranibizumab.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ranibizumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ranibizumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ranibizumab.
Advertisement
Belimumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Belimumab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Ranibizumab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Ranibizumab.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranibizumab.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Ranibizumab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Ranibizumab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Ranibizumab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Ranibizumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Ranibizumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ranibizumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ranibizumab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Ranibizumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ranibizumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranibizumab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Ranibizumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ranibizumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ranibizumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Ranibizumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Ranibizumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ranibizumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ranibizumab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Ranibizumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ranibizumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Ranibizumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Ranibizumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ranibizumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Ranibizumab.
